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Background. Identifying polio vaccine regimens that can elicit robust intestinal mucosal immunity and interrupt viral transmis-
sion is a key priority of the polio endgame.
Methods. In a 2013 Chilean clinical trial (NCT01841671) of trivalent inactivated polio vaccine (IPV) and bivalent oral polio 
vaccine (bOPV; targeting types 1 and 3), infants were randomized to receive IPV-bOPV-bOPV, IPV-IPV-bOPV, or IPV-IPV-IPV 
at 8, 16, and 24 weeks of age and challenged with monovalent oral polio vaccine type 2 (mOPV2) at 28 weeks. Using fecal samples 
collected from 152 participants, we investigated the extent to which IPV-bOPV and IPV-only immunization schedules induced 
intestinal neutralizing activity and immunoglobulin A against polio types 1 and 2.
Results. Overall, 37% of infants in the IPV-bOPV groups and 26% in the IPV-only arm had detectable type 2–specific stool neu-
tralization after the primary vaccine series. In contrast, 1 challenge dose of mOPV2 induced brisk intestinal immune responses in all 
vaccine groups, and significant rises in type 2–specific stool neutralization titers (P < .0001) and immunoglobulin A concentrations 
(P < 0.0001) were measured 2 weeks after the challenge. In subsidiary analyses, duration of breastfeeding also appeared to be associ-
ated with the magnitude of polio-specific mucosal immune parameters measured in infant fecal samples.
Conclusions. Taken together, these results underscore the concept that mucosal and systemic immune responses to polio 
are separate in their induction, functionality, and potential impacts on transmission and, specifically, provide evidence that pri-
mary vaccine regimens lacking homologous live vaccine components are likely to induce only modest, type-specific intestinal 
immunity.
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The Global Polio Eradication Initiative successfully completed 
a worldwide replacement of the trivalent oral polio vaccine 
(tOPV) with a bivalent types 1 and 3 oral polio vaccine (bOPV) 
in spring 2016 [1]. The withdrawal of live serotype 2 poliovi-
rus from the oral polio vaccines (OPVs) delivered in routine 
immunization programs was coupled with country-level com-
mitments to introduce at least 1 dose of the trivalent inacti-
vated polio vaccine (IPV) [2]. This global switch represents an 
important advance for efforts to prevent vaccine-associated 
paralytic poliomyelitis cases [3] and to mitigate risks of intro-
ducing new circulating vaccine-derived polioviruses from the 
type 2 component of the oral vaccine [4]. Nevertheless, the 
implications of IPV-only and IPV-bOPV immunization sched-
ules for the acquisition of mucosal immunity to polio remain 
uncertain.
In a similar way to how vaccine-induced systemic immunity 
is important for the prevention of paralytic poliomyelitis, vac-
cine-induced mucosal immunity is critical for the interruption 
of poliovirus transmission and, therefore, of paramount impor-
tance in the journey towards global polio eradication [5, 6]. 
Although IPV-driven immunization schedules have success-
fully eliminated polio from high-income regions via improved 
sanitation and hygiene practices, particularly where oral-oral 
rather than fecal-oral transmission predominated, such as 
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Scandinavia and the Netherlands (reviewed in [7]), the capacity 
of IPV to block intestinal viral shedding upon challenge with 
live OPV viruses appears to be limited [8–10]. For example, in 
a Baltimore-based cohort, 85% of participants who had been 
immunized with IPV at 2, 4, and 15 months of age excreted 
polioviruses when challenged with tOPV at 18 months [11]. 
Similarly, in a Cuban cohort free of environmental expos-
ure to OPV-derived viruses, infants immunized with 2 and 
3 doses of IPV shed tOPV challenge virus at titers only 
modestly lower than the titers of control infants who had no 
prior polio experience (mean log10 viral titers, respectively: 
3.46, 3.37, and 3.89) [12].
The present study complements this research and uses state-
of-the-art immunoassays to investigate the extent to which 
primary immunization schedules, incorporating up to 3 doses 
of IPV, are capable of inducing mucosal immunity specific 
to polio types 1 and 2 [13]. For this open-label clinical trial, 
Chilean infants were randomized to receive 1 of 3 immuni-
zation schedules (ie, IPV-bOPV-bOPV, IPV-IPV-bOPV, or 
IPV-IPV-IPV) at 8, 16, and 24 weeks of age, followed by an 
mOPV2 challenge at 28 weeks. The trial’s principal findings, 
reported by O’Ryan et  al., showed that, although all 3 vac-
cine regimens were associated with strong systemic responses 
against poliovirus types 1 and 3 and IPV dose-dependent sys-
temic responses against poliovirus type 2, the vast majority 
of participants had detectable viral shedding in their stools 1 
week after the mOPV2 challenge, regardless of their primary 
vaccine schedule [14]. The current results further advance 
our understanding of vaccine-induced mucosal immunity to 
poliovirus by providing new evidence that boosting serum 
neutralization via repeated doses of IPV does not, in turn, 
augment intestinal neutralizing activity or immunoglobulin 
A (IgA) levels. Instead, the results show that the induction of 
robust intestinal immunity is largely conditional on the receipt 
of homologous live vaccines. Finally, the evidence shows that 
the duration of breastfeeding may influence the magnitude 
of polio-specific mucosal immune parameters measured in 
infant fecal samples.
MATERIALS AND METHODS
Selection of Study Participants
The design of the phase 4, randomized, open-label, non-inferi-
ority study (NCT01841671) undertaken between 25 April and 
1 August 2013 has been previously described [14]. Participants 
included healthy, singleton infants aged 8 weeks (± 7 days) at 
the time of enrollment and excluded infants who: (1) had been 
previously vaccinated against poliovirus, (2) had a low birth 
weight (ie, <2500 g), (3) resided in a household with someone 
who had received OPV within the previous 6  months or was 
scheduled to receive OPV in the following 6 months, (4) had 
a confirmed or suspected immunosuppressive or immunodefi-
ciency condition, (5) had a family history of immunodeficiency, 
(6) had a major congenital defect or serious chronic illness, (7) 
had a known allergy to any component of the vaccines, (8) had 
an uncontrolled blood disorder contraindicating intramuscular 
injections, (9) was or would be administered immunoglobulins 
and/or blood products since birth or during the study period, or 
(10) was deemed unfit for inclusion in the study based on inves-
tigator discretion. For the present analyses, 183 participants 
were selected at random from the 537 participants included in 
the per-protocol analysis of the original trial (ie, the subset of 
participants who received all 3 immunizations specified for the 
primary vaccine schedule; Figure 1). From this group of partic-
ipants, an analytical cohort comprising 152 infants was selected 
after the exclusion of individuals who were missing mOPV2 
shedding data from the 28, 29, 30, 31, or 32 week visits and/
or stool neutralization/IgA data from the 28 and 30 week visits 
(Figure 1).
Laboratory Procedures
Stool samples collected from the study participants at 28, 29, 30, 
31, and 32 weeks of age (ie, on the day of mOPV2 challenge and 
at weekly intervals over the subsequent 4 weeks) were shipped 
frozen to the Geisel School of Medicine at Dartmouth College 
(Lebanon, New Hampshire) for further investigation of intes-
tinal mucosal immunity using methods described previously 
[8, 9, 15, 16]. Whereas mucosal immunity to polio type 2 was 
Participants included in the per-protocol analysis of NCT 01841671 (N=537)
Per-protocol recipients of
IPV-bOPV-bOPV (N=175)
Per-protocol recipients of 
IPV-IPV-bOPV (N=184)
Per-protocol recipients of 
IPV-IPV-IPV (N=178)
Participants randomly selected for potential inclusion in current analyses (N=183)
Selected recipients of
IPV-bOPV-bOPV (N=60)
Selected recipients of
IPV-IPV-bOPV (N=64)
Selected recipients of
IPV-IPV-IPV (N=59)
Excluded (N=12)a
Missing study visits (N=6)
Missing shedding data (N=2)b
Missing stool neut./IgA data (N=5)c
Excluded (N=10)a
Missing study visits (N=6)
Missing shedding data (N=4)b
Missing stool neut./IgA data (N=2)c, d
Excluded (N=9)a
Missing study visits (N=4)
Missing shedding data (N=4)b
Missing stool neut./IgA data (N=2)c, d
Included recipients of
IPV-bOPV-bOPV (N=48)e
Included recipients of
IPV-IPV-bOPV (N=54)e
Included recipients of
IPV-IPV-IPV (N=50)
Figure 1. Flow diagram for the selection of the analytical cohort from NCT 01841671, an investigation of the “Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants 
Primed with IPV Vaccine (IPV002ABMG),” undertaken in Santiago, Chile, between 25 April and 1 August 2013. Abbreviations: bOPV, bivalent oral polio vaccine; IgA, immu-
noglobulin A; IPV, trivalent inactivated polio vaccine; neut., neutralization. aReasons for exclusion are not mutually exclusive. bSubjects with missing type 2 oral poliovirus 
vaccine shedding data from at least 1 visit at 28, 29, 30, 31, or 32 weeks of age. cSubjects with missing polio type 2–specific stool neutralization and immunoglobulin A data 
from at least 1 visit at 28 or 30 weeks of age. dPolio type 1–specific immunoglobulin A data were missing from the visit at 30 weeks of age in 2 of the included subjects in 
the IPV-IPV-bOPV group and 1 in the IPV-IPV-IPV group. eType 1– and 2–specific serum neutralization data were missing from the visits at 28 and/or 29 weeks of age in 1 of 
the included subjects in the IPV-IPV-bOPV group and 3 in the IPV-bOPV-bOPV group.
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the primary endpoint of interest, mucosal immunity to polio 
type 1 was also investigated as a comparator endpoint, reflect-
ing that bOPV-receiving groups had exposure to a homologous 
live vaccine in the primary immunization series. The stool neu-
tralization titers needed to achieve 60% neutralization were 
determined by limiting dilution inhibition of luciferase-labe-
led type-specific polio pseudoviruses in vitro, as previously 
described [16]: titers greater than 1:512 (ie, the highest dilution 
tested) were recorded at 1:1024; those less than 1:4 (ie, the lowest 
dilution tested) were recorded at 1:2. Total and polio type–spe-
cific concentrations of IgA in stool specimens were quantified, 
relative to a serum standard, using a multivariate microsphere 
assay developed by coupling monovalent IPVs to fluorescent-
ly-coded magnetic microspheres [15]. Vaccine group assign-
ments were unblinded to the Dartmouth team only after sample 
testing and initial statistical analyses were completed.
As described in the parent study, serum neutralization titers 
and viral shedding were determined at the Centers for Disease 
Control and Prevention (Atlanta, Georgia) [14]. Type-specific 
serum neutralizing activity was evaluated using the World 
Health Organization’s standard microneutralization assay [17]. 
Poliovirus shedding levels were expressed as the log10 50% cell 
culture infective dose (CCID50) per gram of stool. Samples 
with mOPV2 shedding below the limit of detection (ie, 102.75 
CCID50/mL) were recorded at a log10 CCID50 of 0. A viral shed-
ding index was estimated, following the methods of Asturias 
et al. [18], as the mean of stool log10 type 2 viral titers at weeks 
1, 2, 3, and 4 post-challenge (ie, 29, 30, 31, and 32 weeks of age). 
Breastfeeding data were obtained via telephone survey or dir-
ectly from the clinical file; mothers were asked whether their 
participating infants were receiving breastmilk at 8, 16, 24, and 
29 weeks of age.
Statistical Analyses
For the statistical analyses, infants were categorized by vaccine 
group assignment (ie, IPV-bOPV-bOPV, IPV-IPV-bOPV, and 
IPV-IPV-IPV) and by reported duration of breastfeeding (ie, 
whether or not the child was receiving breastmilk at 29 weeks of 
age). Differences in the distributions of the type-specific serum 
and stool neutralization titers and mucosal IgA levels across vac-
cine regimens were evaluated using Kruskal-Wallis tests; Dunn’s 
tests with Bonferroni corrections estimated within each com-
parative trio were used to compare pairs of vaccine schedules 
for post-estimation hypothesis testing. Type-specific changes in 
the immune parameters following the mOPV2 challenge were 
evaluated within each of the vaccine groups using Wilcoxon 
matched-pairs signed ranks tests. Correlations between immune 
parameters were estimated using Spearman’s rank correlation 
coefficients and visualized by scatter plot. Longitudinal patterns 
in the intestinal immune response to the mOPV2 challenge 
were explored using boxplots in a randomly-selected subgroup 
of 20 infants. Differences in the proportions of infants with 
detectable levels of mOPV2 shedding across vaccine regimens 
were compared using Pearson’s chi-squared tests. Distributions 
of the type 2–specific stool neutralization titers and IgA levels at 
the 28 and 30 week study visits across breastfeeding categories 
were compared using Mann-Whitney U tests. Differences in 
the shedding index endpoint were estimated using multivariate 
linear regression. The association between breastfeeding sta-
tus and detection of type 2–specific stool neutralization at the 
time of the challenge was investigated using a univariate logistic 
regression. All P values are from 2-sided statistical tests, and all 
analyses were performed using Stata, version 13.0 (StataCorp 
LP, College Station, Texas) and R, version 3.2.5.
Ethics
The Dartmouth College Committee for the Protection of 
Human Subjects and local ethics committees from the Faculty 
of Medicine at the University of Chile, the Servicio de Salud 
Metropolitano Norte, and the Servicio de Salud Metropolitano 
Sud approved the study. The original informed consent from 
parents/guardians included provisions for the use of samples in 
future polio-related studies, so further consenting was judged 
unnecessary.
RESULTS
In the present analyses, polio serotype–specific neutralizing 
activity and IgA concentrations were evaluated in 364 stool 
samples from 152 infants, representing approximately one-
third of the participants in the per-protocol analysis of the 
primary study. In the trial, children were administered IPV-
bOPV-bOPV (n = 48), IPV-IPV-bOPV (n = 54), or IPV-IPV-
IPV (n = 50) at 8, 16, and 24 weeks of age and then challenged 
with mOPV2 at 28 weeks. Total IgA was successfully detected 
in all stool samples, and the median total concentration of IgA 
in the stool suspensions at 28 weeks of age was determined to 
be 94 800 ng/mL (interquartile range: 45 950 to 221 500). The 
“take” of the challenge vaccine was high, as more than 95% 
of participants (n  =  145/152) had mOPV2 shedding and/or 
detectable type 2–specific stool  neutralizing activity over the 
duration of follow-up. Of note, type 2–specific viral shedding 
was detected during the 28-week visit in 1 infant from each of 
the 3 vaccine groups, suggesting that some participants in the 
trial were environmentally exposed to Sabin viruses prior to 
receipt of the live vaccine challenge.
Effects of IPV-bOPV and IPV-only Immunization Schedules on Markers of 
Immunity to Polio Types 1 and 2
Consistent with previously-reported findings [14], the primary 
vaccine series induced strong type 2–specific serum neutraliza-
tion responses in more than 97% (n = 146/150) of the partici-
pants (Figure 2). The magnitude of serum neutralizing activity 
increased in an IPV dose-dependent manner, such that serum 
neutralization was significantly higher in the groups receiving 
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either 2 or 3 doses of IPV compared with the group receiving a 
single IPV dose (Figure 2). In contrast, only 26% (n = 13/50) in 
the IPV-only arm and 37% (n = 38/102) of infants in the IPV-
bOPV groups had detectable type 2–specific stool neutralizing 
activity after the primary immunization schedules (P  =  .17, 
Chi-squared test; Figure 2). Further, type 2–specific serum neu-
tralization was not significantly correlated with either the rela-
tive concentration of type 2–specific stool IgA at the time of the 
challenge nor with the titer of peak viral shedding recorded at 
1 week post-challenge (Supplementary Figure 1). An analogous 
disconnect between the serum and mucosal immune markers 
specific to polio type 1 was observed in the infants that received 
the IPV-only immunization schedule. While all 50 participants 
who received IPV alone had detectable type 1–specific serum 
neutralization at the time of the mOPV2 challenge, only 28% 
(n  =  14/50) had detectable type 1–specific stool neutraliza-
tion. By contrast, whereas 99% of the infants in the IPV-bOPV 
groups had detectable type 1–specific serum neutralization at 
the time of mOPV2 challenge, 89% (n = 89/100), had detect-
able type 1–specific stool neutralization. Additionally, infants 
who had received at least 1 dose of bOPV had higher reciprocal 
titers of type 1–specific serum neutralization and stool concen-
trations of type 1–specific IgA than their IPV-only counterparts 
(Figure 2).
Effects of IPV-bOPV and IPV-only Immunization Schedules on Intestinal 
Immune Responses to Live Vaccine Challenge
To investigate the extent to which the intestinal immunity 
induced by the IPV-bOPV and IPV-only immunization sched-
ules has the capacity to provide protection upon subsequent 
exposure to live poliovirus, vaccinated infants were challenged 
with mOPV2 at 28 weeks of age. As previously reported, the 
magnitude of mOPV2 viral shedding peaked at 1 week after the 
challenge (Figure 3). At this time point, the mOPV2-derived 
virus was recovered in stool samples from 82% (n = 125/152) 
of participants, and the prevalence of shedders did not vary 
significantly by primary vaccine group assignment (P  =  .20, 
Chi-squared test). Viral shedding waned steadily over fol-
low-up, and by 4 weeks post-challenge, less than half (47%, 
n = 71/152) of the participants continued to shed the virus. The 
polio type 2–specific mucosal responses appeared to closely 
track the viral replication patterns. Both type 2–specific stool 
Figure 2. Systemic and intestinal immunity to polio types 1 and 2 at the time of the monovalent oral polio vaccine type 2 challenge (28 weeks of age) in infants previously 
immunized with IPV-bOPV-bOPV (n = 48), IPV-IPV-bOPV (n = 54), and IPV-IPV-IPV (n = 50). (A) Serum neutralization specific to poliovirus types 1 (P = .0001) and 2 (P = .0001), (B) 
stool neutralization specific to poliovirus types 1 (P = .0001) and 2 (P = .06), and (C) stool immunoglobulin A specific to poliovirus types 1 (P = .0001) and 2 (P = .004). Overall P 
values are from Kruskal-Wallis tests comparing the distributions of immune markers by primary vaccine group assignment; pairwise P values are from post hoc Dunn’s tests 
with Bonferroni correction for multiple testing within each grouping. Horizontal black bars indicate the median levels. Abbreviations: bOPV, bivalent oral polio vaccine; IgA, 
immunoglobulin A; IPV, trivalent inactivated polio vaccine; mOPV2, monovalent oral polio vaccine type 2.
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neutralization and IgA concentrations began rising 1 week 
after the challenge (Figure 3) and became statistically signif-
icantly higher than baseline levels in all vaccine groups by 2 
weeks post-challenge (Table 1). Levels of type 2–specific stool 
neutralization and IgA 2 weeks after the challenge were highly 
correlated (Spearman’s rho = 0.81, P < .0001) with each other 
and, to a lesser degree, both immune parameters were inversely 
correlated with mOPV2 shedding measured at the same point 
in time (stool neutralization: -0.15, P = .07; IgA: -0.22, P = .007; 
Figure 4).
Of note, differences between the vaccine groups were 
observed in the IgA concentrations measured at the time of the 
challenge and in the overall shedding patterns, suggesting there 
may be some degree of cross-reactivity across polio serotypes. 
Despite not receiving a homologous live vaccine, infants in the 
IPV-bOPV groups had higher type 2–specific stool IgA lev-
els at the time of the challenge than children immunized with 
IPV alone (Table  1; Figure  2). Further, in a linear regression 
adjusted for breastfeeding status at the time of the challenge, 
the shedding index endpoint decreased, on average, by 0.51 
units (95% confidence interval: 0.18 to 0.85, P = .003) for each 
1 standard deviation increase in the log10 type 2–specific stool 
IgA concentration measured at the time of the challenge. By 4 
weeks after the challenge, only 39% (n = 40/102) of the infants 
in the 2 IPV-bOPV study arms continued to shed the virus, as 
opposed to 62% (n = 31/50) of the infants in the IPV-only group 
(P = .02, Chi-squared test). Also, supporting the hypothesis of 
heterotypic immunity, the percentage of children in the IPV-
only group with detectable type 1–specific stool neutralization 
increased from 28% (n = 14/50) at the time of the challenge to 
40% (n = 20/50) 2 weeks after receiving mOPV2.
Potential Association Between Breastfeeding and Intestinal Immunity to 
Polio Type 2
In addition to vaccine group assignment, duration of breast-
feeding was another variable that was associated with the lev-
els of intestinal immune markers measured in stool samples. 
Participants whose mothers reported breastfeeding through 
29 weeks of age (ie, up through and beyond the time of the 
mOPV2 challenge) had 2.5-fold higher odds (95% confidence 
Figure 3. Polio type 2–specific intestinal immune responses to mOPV2 challenge in a random subgroup of infants (n = 20). (A) mOPV2 shedding, (B) type 2–specific stool 
neutralization, and (C) type 2–specific stool immunoglobulin A. Blue, circle-shaped markers indicate infants immunized with IPV-bOPV-bOPV (n = 7); orange, triangle-shaped 
markers indicate infants immunized with IPV-IPV-bOPV (n = 7); and red, square-shaped markers indicate infants immunized with IPV-IPV-IPV (n = 6). Abbreviations: bOPV, biva-
lent oral polio vaccine; IgA, immunoglobulin A; IPV, trivalent inactivated polio vaccine; mOPV2, monovalent oral polio vaccine type 2.
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interval: 1.1 to 5.4, P  =  .02, univariate logistic regression) of 
having detectable type 2 stool neutralization at the time of the 
challenge than their peers with a shorter reported duration of 
breastfeeding. Consistent with this observation, and relative 
to infants without concomitant breastfeeding, infants with 
reported breastfeeding at 29 weeks had significantly higher type 
2 neutralization at 30 weeks of age (ie, 2 weeks post-challenge), 
as well as heightened stool concentrations of type 2–specific 
IgA at the 28 and 30 week visits (Figure 5). The shedding index 
endpoint was also lower, albeit not statistically significantly, in 
the children breastfed through 29 weeks (mean difference after 
adjusting for vaccine group in a multivariate linear regression: 
-0.61; 95% confidence interval, -1.28 to 0.06; P = .07).
DISCUSSION
The substitution of the live type 2 component from oral polio 
vaccines for its inactivated counterpart represents a major 
step in the polio eradication endgame and serves as a pro-
grammatic precursor for the eventual cessation of all OPV 
use. However, along with introducing important opportu-
nities for mitigating the risk of vaccine-associated paralytic 
Table 1. Poliovirus Types 1– and 2–Specific Serum and Intestinal Immune Responses to the Monovalent Oral Polio Vaccine Type 2 Challenge in Infants 
Previously Immunized With IPV-bOPV-bOPV, IPV-IPV-bOPV, and IPV-IPV-IPV 
Immune Marker
Weeks After 
Challenge
Weeks 
of Age
IPV-bOPV-bOPV (n = 48) IPV-IPV-bOPV (n = 54) IPV-IPV-IPV (n = 50)
P Value, 
Between 
GroupsbMedian (IQR)
P Value, 
Between 
Visitsa Median (IQR)
P Value, 
Between 
Visitsa Median (IQR)
P Value, 
Between 
Visitsa
Type 1 Serum Neutralization, 0 28 10.5 (10.5, 10.5) .11 10.5 (10.5, 10.5) .10 9.5 (8.8, 10.2) .0004 .0001
Log2 Reciprocal Titer 1 29 10.5 (10.5, 10.5) 10.5 (10.5, 10.5) 9.2 (8.5, 10.2) .0001
Stool Neutralization, 0 28 6.9 (5.3, 8.6) .45 7.4 (3.8, 8.9) .58 1.0 (1.0, 3.6) .41 .0001
Log2 Reciprocal Titer 2 30 7.4 (5.6, 8.9) 8.0 (3.9, 10) 1.0 (1.0, 3.5) .0001
Stool Immunoglobulin A, 0 28 -0.8 (-1.3, -0.6) .59 -0.8 (-1.3, -0.5) .30 -1.6 (-1.9, -1.2) .56 .0001
Log10 Relative 
Concentration Units
2 30 -0.9 (-1.1, -0.4) -0.8 (-1.1, -0.5) -1.5 (-1.9, -1.2) .0001
Type 2 Serum Neutralization, 0 28 5.8 (3.8, 7.5) <.0001 9.5 (7.2, 10.5) <.0001 9.8 (9.2, 10.5) .0023 .0001
Log2 Reciprocal Titer 1 29 8.5 (5.2, 10.2) 10.5 (8.5, 10.5) 10.5 (9.5, 10.5) .0001
Stool Neutralization, 0 28 1.0 (1.0, 2.8) <.0001 1.0 (1.0, 5.6) <.0001 1.0 (1.0, 2.0) <.0001 .06
Log2 Reciprocal Titer 2 30 8.5 (6.1, 10) 8.6 (4.3, 10) 8.6 (6.6, 10) .74
Stool Immunoglobulin A, 0 28 -2.0 (-2.7, -1.5) <.0001 -1.9 (-2.6, -1.6) <.0001 -2.5 (-3.1, -2.0) <.0001 .004
Log10 Relative 
Concentration Units
2 30 -0.4 (-1.2, 0.1) -0.3 (-1.2, 0.2) -0.5 (-1.1, 0.2) .96
Data shown are from NCT 01841671, undertaken in Santiago, Chile, between 25 April and 1 August 2013 (N = 152). 
Abbreviations: bOPV, bivalent oral polio vaccine; IPV, trivalent inactivated polio vaccine; IQR, interquartile range. 
aP values are from Wilcoxon matched-pairs signed-ranks tests. 
bP values are from Kruskal-Wallis tests.
Figure 4. Pairwise correlations between type 2–specific stool neutralization, immunoglobulin A, and mOPV shedding 2 weeks after mOPV2 challenge (ie, 30 weeks of age). 
Abbreviations: bOPV, bivalent oral polio vaccine; IgA, immunoglobulin A; IPV, trivalent inactivated polio vaccine; mOPV2, monovalent oral polio vaccine type 2.
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poliomyelitis and the circulation of OPV2-derived strains, 
potential risks are associated with the withdrawal of live polio 
vaccines from immunization programs. Our findings indicate 
that, despite their demonstrated ability to elicit strong type 2 
serum neutralization, IPV-bOPV and IPV-only immunization 
schedules induce limited type 2–specific intestinal neutraliz-
ing activity and IgA responses. Similarly, whereas robust type 
1 serum immunity was induced regardless of vaccine group 
assignment, infants who received IPV alone were observed to 
have inferior type 1 intestinal immunity relative to their peers 
who had received at least 1 dose of bOPV as part of their pri-
mary vaccine schedule. When challenged with mOPV2, high 
levels of the mOPV2 virus were recovered from the stools of 
infants in each of the immunization groups, and almost half of 
all study participants continued to shed the virus 4 weeks after 
the challenge. Overall, these results substantiate concerns that 
populations with polio immunity driven by inactivated rather 
than live vaccines have the potential to act as conduits of 
transmission if OPV and/or wild poliovirus strains remain in 
circulation [19], such as was observed in the case of the 2013 
silent outbreak of wild poliovirus type 1 in an IPV-vaccinated 
Israeli population [20, 21].
Although the relative protection afforded by polio vaccines is 
most commonly inferred from changes in serum antibody lev-
els, a growing number of studies, 18 of which were meta-ana-
lyzed by Hird and Grassly [10], have used an OPV challenge 
Figure 5. Intestinal immunity to polio type 2 at the time of and 2 weeks after monovalent oral polio vaccine type 2 challenge (ie, 28 and 30 weeks of age) by reported 
duration of breastfeeding. P values are from Mann-Whitney U tests comparing the distributions of immune markers by breastfeeding category. Horizontal black bars indicate 
the median levels. Blue, circle-shaped markers indicate infants immunized with IPV-bOPV-bOPV (n = 48); orange, triangle-shaped markers indicate infants immunized with IPV-
IPV-bOPV (n = 54); and red, square-shaped markers indicate infants immunized with IPV-IPV-IPV (n = 50). Abbreviations: bOPV, bivalent oral polio vaccine; IgA, immunoglobulin 
A; IPV, trivalent inactivated polio vaccine; mOPV2, monovalent oral polio vaccine type 2.
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model and its resultant viral shedding as a proxy measure of 
mucosal immunity. The current study advances our under-
standing of the OPV challenge system by directly measuring 
mucosal functional activity and antibody levels and defining 
their correlations with viral shedding. Furthermore, the pres-
ent investigation of type 1–specific mucosal immunity to polio-
virus provides proof of concept that, moving forward, it may 
be plausible to investigate vaccine-induced mucosal immunity 
to polio in the absence of an OPV challenge. In conjunction 
with the global withdrawal of OPVs, such an approach could 
be deemed necessary to eliminate the risks of introducing 
circulating vaccine-derived polioviruses to the environment. 
Moreover, a direct measurement of mucosal neutralizing activi-
ties and antibody responses may enable investigators to evaluate 
the intestinal immune impacts of novel vaccine candidates (eg, 
new, highly-attenuated, and genetically stable OPVs) in a dose-
by-dose manner.
Broadly, our results, which found minimal intestinal immune 
responses even after 3 doses of IPV, align with earlier IPV-only 
shedding studies that have shown the odds of excreting a type 
2 poliovirus after an OPV challenge are similar between unvac-
cinated children and those who received 2 [22] or 3 [12] doses 
of IPV. The findings are also consistent with shedding studies 
of IPV-bOPV mixed schedules, which have demonstrated that 
the addition of IPV to a primary bOPV schedule only margin-
ally reduces the type 2 viral shedding index [18] and, indeed, 
that the odds of household transmission remain significantly 
higher in IPV-bOPV recipients relative to their tOPV-receiving 
counterparts [23]. Differing from these patterns, 4 studies in 
Indian children residing in regions with low OPV effectiveness 
[24] have provided evidence that a late, supplementary dose of 
IPV following multiple OPV immunizations can boost intes-
tinal immunity for up to 11  months, as indicated by reduced 
poliovirus shedding following a bOPV challenge [25–27] 
and increased counts of serum antibody–secreting cells with 
mucosal homing markers [28]. Thus, the previous receipt of an 
OPV may prime children for IPV-induced intestinal mucosal 
responses that are comparable or better than responses to an 
additional dose of OPV.
In this study, approximately one-third of the cohort had 
detectable—albeit mostly low—type 2–specific stool neutral-
izing activity at the time of the challenge. The source of this 
underlying immunity remains poorly defined. As trivalent 
OPV was still being administered in the country at the time 
of the trial and as 3 infants were shedding prior to the chal-
lenge, some degree of passive exposure to Sabin-like viruses is 
probable. Another possibility is that the bOPV vaccine in the 
primary series could have had some degree of cross-reactivity, 
augmenting the type 2–specific IgA levels in the stool samples. 
Additionally, the subsidiary analyses provide intriguing, pre-
liminary evidence that breastfeeding may be positively associ-
ated with mucosal immune indicators in the context of polio 
immunization, in line with several earlier studies of breastfeed-
ing and serum neutralizing activity [29, 30]. Further research is 
needed to disentangle the relative contributions of breastfeed-
ing-associated factors, such as the transfer of secreted IgA [31], 
programming of the gut microbiome [32, 33], and stimulation 
of infant intestinal IgA production, which could potentially 
underlie the observed enhancement of mucosal responses in 
concurrently breast-fed infants.
In sum, our study of Chilean infants’ mucosal immune 
responses to IPV-bOPV and IPV-only immunization sched-
ules reinforces the concept that mucosal and systemic 
responses to polio vaccination are remarkably separate in 
their induction, functionality, and role in clinical protection 
against poliovirus and its transmission. Systemic (humoral) 
immunity is key to the prevention of paralytic poliomyelitis 
but, in the context of global eradication, mucosal immunity 
is equally essential through its role in halting intestinal viral 
shedding and, thereby, interrupting the fecal-oral transmis-
sion of both wild and vaccine-derived polioviruses. Indeed, 
if IPV does not substantively limit enteric viral replication 
on subsequent exposure to live polioviruses, children who 
live in conditions that favor fecal-oral transmission and those 
who have not received a vaccine with a live poliovirus type 
2 component will potentially be at continued vulnerability to 
infection as long as OPV2-derived strains persist in the envir-
onment and/or could be re-introduced (eg, via laboratory 
[34] or manufacturing containment failures [35], or importa-
tion by immunocompromised long-term shedders of OPV2-
derived viruses [36]).
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